JH-X-119-01 is a highly selective (significantly inhibited only YSK4 and MEK3 in a panel of over 300 kinases) and potent (IC50 = 9 nM) covalent inhibitor of interleukin 1 receptor-associated kinase 1 (IRAK1). It displayed cytotoxic activity against several lymphoma cell lines and exhibited synergism with the BTK inhibitor Ibrutinib in the same systems. JH-X-119-01 protected mice from LPS-induced sepsis2 and ameliorated acute graft-versus-host disease in mice undergoing allogenic hematopoietic cell transplantation without effecting the anti-lymphoma effect3.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten